Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
17.59
+0.31 (1.79%)
At close: Dec 20, 2024, 4:00 PM
17.20
-0.39 (-2.22%)
After-hours: Dec 20, 2024, 4:21 PM EST
Entrada Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for TRDA stock have an average target of 24.75, with a low estimate of 20 and a high estimate of 29. The average target predicts an increase of 40.70% from the current stock price of 17.59.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for TRDA stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 3 | 3 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Strong Buy Initiates $29 | Strong Buy | Initiates | $29 | +64.87% | Dec 5, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $25 → $28 | Buy | Maintains | $25 → $28 | +59.18% | Nov 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $20 | Strong Buy | Maintains | $18 → $20 | +13.70% | Nov 6, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $25 | Buy | Reiterates | $25 | +42.13% | Aug 26, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +2.33% | Aug 14, 2024 |
Financial Forecast
Revenue This Year
190.23M
from 129.01M
Increased by 47.45%
Revenue Next Year
47.67M
from 190.23M
Decreased by -74.94%
EPS This Year
1.07
from -0.20
EPS Next Year
-3.15
from 1.07
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 199.4M | 63.0M | 63.0M | |||
| Avg | 190.2M | 47.7M | 39.6M | |||
| Low | 181.3M | 34.3M | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 54.5% | -66.9% | 32.2% | |||
| Avg | 47.5% | -74.9% | -17.0% | |||
| Low | 40.5% | -82.0% | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 1.32 | -2.28 | -2.03 |
| Avg | 1.07 | -3.15 | -3.23 |
| Low | 0.89 | -3.67 | -4.41 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.